nimbex
aspen pharma trading limited - cisatracurio - cisatracurio
cardura
four pharma clinical research organization - doxazosina - doxazosina
virbagen omega
virbac s.a. - interferone omega ricombinante di origine felina - immunostimolanti, - dogs; cats - dogsreduction of mortality and clinical signs of parvovirosis (enteric form) in dogs from one month of age. catstreatment of cats infected with feline leukaemia virus (felv) and / or feline immunodeficiency virus (fiv), in non-terminal clinical stages, from the age of nine weeks. in a field study conducted, it was observed that there was:a reduction of clinical signs during the symptomatic phase (four months);a reduction of mortality:in anaemic cats, mortality rate of about 60% at four, six, nine and 12 months was reduced by approximately 30% following treatment with interferon;in non-anaemic cats, mortality rate of 50% in cats infected by felv was reduced by 20% following treatment with interferon. nei gatti infetti da fiv, la mortalità era bassa (5%) e non era influenzata dal trattamento.
starline four dimension day cream 50ml
s.i.r.p.e.a. spa -
starline four dimension night cream 50ml
s.i.r.p.e.a. spa -
blenrep
glaxosmithkline (ireland) limited - belantamab mafodotin - mieloma multiplo - agenti antineoplastici - blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.
rimadyl compressa appetibile da 20 mg (a.i.p.)
four pharma cro srl - carprofen - carprofen - 20 milligrammo (i), carprofen - 20 mg - carprofen
qtern
astra zeneca ab - saxagliptin, dapagliflozin propandiolo monoidrato - diabetes mellitus, type 2; diabetes mellitus; nutritional and metabolic diseases; metabolic diseases; glucose metabolism disorders - farmaci usati nel diabete - qtern, combinazione a dose fissa di saxagliptin e dapagliflozin, è indicato in adulti di età compresa tra 18 anni e anziani con diabete mellito di tipo 2:migliorare il controllo glicemico quando la metformina e/o una sulfonilurea (su) e uno dei monocomponents di qtern non forniscono un adeguato controllo glicemico,quando già in trattamento con la combinazione libera di dapagliflozin e saxagliptin. (vedere sezioni 4. 2, 4. 4, 4. 5 e 5. 1 per i dati disponibili sugli abbinamenti studiati.